Skip to main content
Premium Trial:

Request an Annual Quote

Biolog, Cellomics, GPC Biotech Awarded US Patents

Premium

Biolog has received US Patent No. 6,727,076, “Comparative phenotype analysis.” The patent describes an invention related to growing and testing microorganisms in a multitest format utilizing a gel forming matrix for the rapid screening of clinical and environmental cultures, the abstract states. The invention is suited for the characterization of commonly encountered microorganisms (e.g., E. coli, S. aureus, etc.), as well as commercially and industrially important organisms from various and diverse environments (e.g., particularly for the growth and characterization of the actinomycetes and fungi). It is also particularly suited for comparative analysis of phenotypic differences between cell types, including strains of microorganisms that have been designated as the same genus and species, as well as other cell types (e.g., mammalian, insect, and plant cells), the abstract states.


Cellomics has received US Patent No. 6,727,071, “System for cell-based screening.” The patent describes an invention that provides systems, methods, and screens for an optical system analysis of cells, to rapidly determine the distribution, environment, or activity of fluorescently labeled reporter molecules. These activities are aimed at screening large numbers of compounds to find ones that specifically affect particular biological functions, the abstract states. The invention involves providing cells containing fluorescent reporter molecules in an array of locations and scanning numerous cells in each location with a high magnification fluorescence optical system, converting the optical information into digital data, and utilizing the digital data to determine the distribution, environment, or activity of the fluorescently labeled reporter molecules in the cells, the abstract states.


GPC Biotech has received US Patent No. 6,727,082, “Assays and reagents for identifying anti-fungal agents, and uses related thereto.” The patent describes an invention for rapid, reliable and effective assays for screening and identifying pharmaceutically effective compounds that specifically inhibit the biological activity of fungal GTPase proteins, particularly GTPases involved in cell wall integrity, hyphael formation, and/or other cellular functions critical to pathogenesis, the abstract states.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.